アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

dispensing solutions, inc. - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - insulin detemir 14.2 mg in 1 ml - levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long acting) insulin for the control of hyperglycemia. levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novo nordisk - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - insulin detemir 100 [iu] in 1 ml - levemir is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. limitations of use levemir is not recommended for the treatment of diabetic ketoacidosis. levemir is contraindicated: risk summary available data from published studies and postmarketing case reports with levemir use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label clinical trial that included 152 pregnant women with type 1 diabetes who were administered levemir once or twice daily, beginning in gestational weeks 8 to 12 or prior to conception, no clear evidence of maternal or fetal risk associated with levemir was observed (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were conducted in non-diabetic pregnant rats and rabbits with insulin detemir administrat

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - insulin detemir 14.2 mg in 1 ml - levemir is indicated to improve glycemic control in adults and children with diabetes mellitus. important limitations of use: - levemir is not recommended for the treatment of diabetic ketoacidosis. intravenous rapid-acting or short-acting insulin is the preferred treatment for this condition. levemir is contraindicated in patients with hypersensitivity to levemir or any of its excipients. reactions have included anaphylaxis [see warnings and precautions (5.4) and adverse reactions (6.1) ] pregnancy category c: in a fertility and embryonic development study, insulin detemir was administered to female rats before mating, during mating, and throughout pregnancy at doses up to 300 nmol/kg/day (3 times a human dose of 0.5 units/kg/day, based on plasma area under the curve (auc) ratio). doses of 150 and 300 nmol/kg/day produced numbers of litters with visceral anomalies. doses up to 900 nmol/kg/day (approximately 135 times a human dose of 0.5 units/kg/day based on auc ratio) were given to rabbits during organoge

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: glycerol; sodium hydroxide; dibasic sodium phosphate dihydrate; water for injections; hydrochloric acid; zinc acetate; metacresol; phenol; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; glycerol; dibasic sodium phosphate dihydrate; metacresol; hydrochloric acid; zinc acetate; water for injections; sodium hydroxide; sodium chloride - treatment of diabetes mellitus. (see 'pharmacology' and 'clinical trials.')

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

a-s medication solutions - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - insulin detemir 100 [iu] in 1 ml - levemir is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. limitations of use levemir is not recommended for the treatment of diabetic ketoacidosis. levemir is contraindicated: risk summary available data from published studies and postmarketing case reports with levemir use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in a randomized, parallel-group, open-label clinical trial that included 152 pregnant women with type 1 diabetes who were administered levemir once or twice daily, beginning in gestational weeks 8 to 12 or prior to conception, no clear evidence of maternal or fetal risk associated with levemir was observed (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were conducted in non-diabetic pregnant rats and rabbits with insulin detemir administrat

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin detemir -

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - insulin - parenteral liquid/solution/suspension - insulin hormone active 40.0 iu/ml - endocrine system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - insulin deficiency

欧州連合 - 英語 - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart, insulin degludec - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

remedyrepack inc. - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - levemir is indicated to improve glycemic control in adults and children with diabetes mellitus. important limitations of use: - levemir is not recommended for the treatment of diabetic ketoacidosis. intravenous rapid-acting or short-acting insulin is the preferred treatment for this condition. levemir is contraindicated in patients with hypersensitivity to levemir or any of its excipients. reactions have included anaphylaxis [ see warnings and precautions (5.5) and adverse reactions (6.1) ]. pregnancy category b risk summary the background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia. female patients should be advised to tell their physician if they intend to become, or if they become pregnant while taking levemir. a randomized controlled clinical trial of pregnant women with type i diabetes using levemir during pregnancy did not show an increase in the risk of fetal abnormal